Coherus BioSciences (CHRS) Reports Q3 EPS of $1.67
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.35 +9.76%
EPS Growth %: +39.4%
Financial Fact:
Gain from sale of office premises: 0
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: +39.4%
Financial Fact:
Gain from sale of office premises: 0
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q3 EPS of $1.67, versus ($1.86) reported last year. Revenue for the quarter came in at $162.8 million, versus $7.2 million reported last year.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Lumentum shares rise on analyst upgrades, AI demand outlook
- Arrive AI and DXC Technology partner to bring delivery tech to factories
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
